{"title":"回顾发现glp -1具有良好的精神病学安全性","authors":"","doi":"10.1002/pu.31345","DOIUrl":null,"url":null,"abstract":"<p>Use of glucagon-like peptide 1 (GLP-1) receptor agonists in patients with diabetes and/or obesity did not increase risk of psychiatric adverse effects or worsening depressive symptoms, a systematic review and meta-analysis has found. Use of GLP-1s in these populations also improved several quality-of-life outcomes. Results of the review and meta-analysis were published online May 14, 2025, in <i>JAMA Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 9","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Review finds GLP-1s have favorable psychiatric safety profile\",\"authors\":\"\",\"doi\":\"10.1002/pu.31345\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Use of glucagon-like peptide 1 (GLP-1) receptor agonists in patients with diabetes and/or obesity did not increase risk of psychiatric adverse effects or worsening depressive symptoms, a systematic review and meta-analysis has found. Use of GLP-1s in these populations also improved several quality-of-life outcomes. Results of the review and meta-analysis were published online May 14, 2025, in <i>JAMA Psychiatry</i>.</p>\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":\"36 9\",\"pages\":\"1-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31345\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31345","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Review finds GLP-1s have favorable psychiatric safety profile
Use of glucagon-like peptide 1 (GLP-1) receptor agonists in patients with diabetes and/or obesity did not increase risk of psychiatric adverse effects or worsening depressive symptoms, a systematic review and meta-analysis has found. Use of GLP-1s in these populations also improved several quality-of-life outcomes. Results of the review and meta-analysis were published online May 14, 2025, in JAMA Psychiatry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
